EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetic variability and use of therapeutic drug monitoring of cannabidiol in patients with refractory epilepsy

Cecilie Johannessen Landmark iD, Johan Sætre, André Gottås, Martha Wolden, Tao Angell-Petersen McQuade, Signe Flood Kjeldsen, Anne Våtevik, Erik Sætre, Torleiv Svendsen, Margrete Larsen Burns, Elisabeth Leere Øiestad, Svein I Johannessen

Epilepsia · 2025-05 · 66 (5) · 1477-1491

DOI: 10.1111/epi.18284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, online erschienen am 22.02.2025. Verfasst von Cecilie Johannessen Landmark und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway. Hauptthemen laut MEDLINE: Cannabidiol, Drug Monitoring, Drug Resistant Epilepsy, Anticonvulsants. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cannabidiol (CBD) (Epidyolex) is a new antiseizure medication (ASM) for rare and severe epileptic syndromes. We aimed to investigate the pharmacokinetic variability of CBD to elucidate relationships between doses, serum concentrations, metabolites, and biochemical markers of toxicity by using therapeutic drug monitoring (TDM) data.

Methods

Data on serum concentrations of all ASMs, CBD, and the active metabolite 7‐hydroxy‐cannabidiol (7‐OH‐CBD) were collected (January 2022 to June 2023) at the Section for Clinical Pharmacology, National Centre for Epilepsy, Oslo University Hospital.

Results

Data from 52 patients were included: 122 serum concentration measurements (1–7 per patient); 48% female, mean age 23 (range 3–55) years. At maintenance ( n = 34), the mean daily dose was 535 (SD 224) mg, that is, 10.03 (standard deviation [SD] .49) mg/kg/day, serum concentration .26 (SD .14) for CBD and .13 (SD .10) μmol/L for 7‐OH‐CBD. Reference ranges of .15–.50 μmol/L for CBD and .04–.25 μmol/L for 7‐OH‐CBD are proposed, which included 80% of measurements. There was a linear correlation between CBD dose to concentration and CBD to CBD‐7‐OH concentrations ( r 2 = .39 and .38) ( p < .05). The hepatic marker alanine aminotransferase (ALT) increased on average 37%, demonstrating a moderate effect on liver function. Intra‐individual coefficients of variation (CVs) were 32% (SD 17) for CBD and 48% (SD 24) for 7‐OH‐CBD ( n = 15, ≥3 measurements). Twenty different ASMs were used: clobazam ( n = 24), valproate ( n = 17), and stiripentol ( n = 8) were most common. The mean concentration ratio of desmethyl‐clobazam/clobazam increased by 140% (7.29–17.5; p < .05) but was variable, pointing to enzyme inhibition by CBD. Significance This observational study with TDM data revealed extensive pharmacokinetic variability of CBD in patients with refractory epilepsy. The results demonstrate the need for close follow‐up and use of TDM, including biochemical markers of toxicity, for individualized treatment with CBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolDrug MonitoringDrug Resistant EpilepsyAnticonvulsantsHumansFemaleMaleAdultMiddle AgedYoung AdultAdolescentChildChild, Preschool

Stichwörter der Autor:innen

CBDbiochemical markerslong‐term therapeutic drug monitoringpharmacokinetic interactions

Substanzen

CannabidiolAnticonvulsants

Autor:innen und Institutionen

  • Department of Pharmacy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
  • Section for Clinical Pharmacology, National Centre for Epilepsy, Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
  • National Centre for Epilepsy, Full member of the ERN EpiCare, Oslo University Hospital, Sandvika, Norway.
  • Department of Forensic Medicine, Oslo University Hospital, Oslo, Norway.
  • Lillehammer Trust Hospital, Lillehammer, Norway.
  • Department of Pharmacy, University of Oslo, Oslo, Norway.

ORCID-Profile: Cecilie Johannessen Landmark

Zitieren

APA

Johannessen Landmark, C., Sætre, J., Gottås, A., Wolden, M., McQuade, T. A., Kjeldsen, S. F., Våtevik, A., Sætre, E., Svendsen, T., Burns, M. L., Øiestad, E. L., & Johannessen, S. I. (2025). Pharmacokinetic variability and use of therapeutic drug monitoring of cannabidiol in patients with refractory epilepsy. Epilepsia, 66(5), 1477-1491. https://doi.org/10.1111/epi.18284

Vancouver

Johannessen Landmark C, Sætre J, Gottås A, Wolden M, McQuade TA, Kjeldsen SF, et al. Pharmacokinetic variability and use of therapeutic drug monitoring of cannabidiol in patients with refractory epilepsy. Epilepsia. 2025;66(5):1477-1491. doi:10.1111/epi.18284

BibTeX
@article{JohannessenLandmark2025,
  author = {Johannessen Landmark, Cecilie and Sætre, Johan and Gottås, André and Wolden, Martha and McQuade, Tao Angell-Petersen and Kjeldsen, Signe Flood and Våtevik, Anne and Sætre, Erik and Svendsen, Torleiv and Burns, Margrete Larsen and Øiestad, Elisabeth Leere and Johannessen, Svein I},
  title = {Pharmacokinetic variability and use of therapeutic drug monitoring of cannabidiol in patients with refractory epilepsy},
  journal = {Epilepsia},
  year = {2025},
  volume = {66},
  number = {5},
  pages = {1477--1491},
  doi = {10.1111/epi.18284}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche